Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

BACKGROUND: PD-1/PD-L1 inhibitors in combination with chemotherapy are widely used in clinical practice. However, the ideal combined timing of them has not been fully explored. METHODS: In this study, simulation experiments to explore the impacts of the combination of anti-PD-1 antibody (anti-PD-1 A...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, W., Zhao, X., Gong, Y., Zhang, M., Zhang, L., Wu, Q., Wu, L., Fan, Z., Yan, X., Jiao, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041717/
https://www.ncbi.nlm.nih.gov/pubmed/33780892
http://dx.doi.org/10.1016/j.esmoop.2021.100094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041717/
https://www.ncbi.nlm.nih.gov/pubmed/33780892
http://dx.doi.org/10.1016/j.esmoop.2021.100094

Ejemplares similares